MHC gene copy number variation in Tasmanian devils: implications for the spread of a contagious cancer

Proc Biol Sci. 2010 Jul 7;277(1690):2001-6. doi: 10.1098/rspb.2009.2362. Epub 2010 Mar 10.

Abstract

Tasmanian devils face extinction owing to the emergence of a contagious cancer. Devil facial tumour disease (DFTD) is a clonal cancer spread owing to a lack of major histocompatibility complex (MHC) barriers in Tasmanian devil populations. We present a comprehensive screen of MHC diversity in devils and identify 25 MHC types and 53 novel sequences, but conclude that overall levels of MHC diversity at the sequence level are low. The majority of MHC Class I variation can be explained by allelic copy number variation with two to seven sequence variants identified per individual. MHC sequences are divided into two distinct groups based on sequence similarity. DFTD cells and most devils have sequences from both groups. Twenty per cent of individuals have a restricted MHC repertoire and contain only group I or only group II sequences. Counterintuitively, we postulate that the immune system of individuals with a restricted MHC repertoire may recognize foreign MHC antigens on the surface of the DFTD cell. The implication of these results for management of DFTD and this endangered species are discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animal Diseases / genetics
  • Animal Diseases / immunology
  • Animal Diseases / transmission*
  • Animals
  • Bites and Stings
  • Endangered Species
  • Facial Neoplasms / genetics
  • Facial Neoplasms / immunology
  • Facial Neoplasms / veterinary*
  • Gene Dosage / genetics*
  • Genetic Variation*
  • Histocompatibility Antigens Class I / genetics
  • Histocompatibility Antigens Class I / immunology
  • Histocompatibility Antigens Class II / genetics
  • Histocompatibility Antigens Class II / immunology
  • Major Histocompatibility Complex / genetics*
  • Marsupialia / genetics*
  • Marsupialia / immunology
  • Molecular Sequence Data
  • Sequence Analysis, DNA

Substances

  • Histocompatibility Antigens Class I
  • Histocompatibility Antigens Class II

Associated data

  • GENBANK/GQ411435
  • GENBANK/GQ411436
  • GENBANK/GQ411437
  • GENBANK/GQ411438
  • GENBANK/GQ411439
  • GENBANK/GQ411440
  • GENBANK/GQ411441
  • GENBANK/GQ411442
  • GENBANK/GQ411443
  • GENBANK/GQ411444
  • GENBANK/GQ411445
  • GENBANK/GQ411446
  • GENBANK/GQ411447
  • GENBANK/GQ411448
  • GENBANK/GQ411449
  • GENBANK/GQ411450
  • GENBANK/GQ411451
  • GENBANK/GQ411452
  • GENBANK/GQ411453
  • GENBANK/GQ411454
  • GENBANK/GQ411455
  • GENBANK/GQ411456
  • GENBANK/GQ411457
  • GENBANK/GQ411458
  • GENBANK/GQ411459
  • GENBANK/GQ411460
  • GENBANK/GQ411461
  • GENBANK/GQ411462
  • GENBANK/GQ411463
  • GENBANK/GQ411464
  • GENBANK/GQ411465
  • GENBANK/GQ411466
  • GENBANK/GQ411467
  • GENBANK/GQ411468
  • GENBANK/GQ411469
  • GENBANK/GQ411470
  • GENBANK/GQ411471
  • GENBANK/GQ411472
  • GENBANK/GQ411473
  • GENBANK/GQ411474
  • GENBANK/GQ411475
  • GENBANK/GQ411476
  • GENBANK/GQ411477
  • GENBANK/GQ411478
  • GENBANK/GQ411479
  • GENBANK/GQ411480
  • GENBANK/GQ411481
  • GENBANK/GQ411482
  • GENBANK/GQ411483
  • GENBANK/GQ411484
  • GENBANK/GQ411485
  • GENBANK/GQ411486
  • GENBANK/GQ411487
  • GENBANK/GQ411488
  • GENBANK/GQ411489
  • GENBANK/GQ411490
  • GENBANK/GQ411491
  • GENBANK/GQ411492
  • GENBANK/GQ411493
  • GENBANK/GU363942
  • GENBANK/GU363943
  • GENBANK/GU363944
  • GENBANK/GU363945
  • GENBANK/GU363946
  • GENBANK/GU363947
  • GENBANK/GU363948